Home - Translational Lung Cancer Research

Translational Lung Cancer Research (TLCR) is now a member of Committee on Publication Ethics (COPE)

Starting from July 2021, AME Publishing Company is formally recognized a publisher member of Committee on Publication Ethics (COPE) and over 60 AME-published journals become a member of Committee on Publication Ethics (COPE), as part of AME’s commitment to best practice in scholarly publishing. Translational Lung Cancer Research (TLCR) is among the list of COPE membership.

Reviewer of the Month (2022)

In 2022, TLCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

New Era of Treatment for Unresectable Locally Advanced Non-Small Cell Lung Cancer

The special series “New Era of Treatment for Unresectable Locally Advanced Non-Small Cell Lung Cancer” of TLCR was guest-edited by Prof. Zhengfei Zhu from Fudan University Shanghai Cancer Center (China), Prof. Xiaolong Fu from Shanghai Chest Hospital (China) and Prof. Steven H. Lin from the University of Texas MD Anderson Cancer Center (USA).

Oligometastatic NSCLC: Definition and Treatment Opportunities

In this series, several crucial aspects of oligometastatic NSCLC lung cancer (OM-NSCLC) are covered, all pertinent to the management of OMD. We believe that some of this knowledge may become useful in the future for the management of stage IV lung cancer in general.

New Impact Factor for Translational Lung Cancer Research: 6.498

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2020 citation year: 6.498.

Immunotherapy in Other Thoracic Malignancies and Uncommon Populations

In this special series of Translational Lung Cancer Research about “Immunotherapy in other thoracic malignancies and uncommon populations”, a group of renowned international specialists involved in the management of thoracic malignancies present a comprehensive and timely review of state-of-the-art of ICI in thoracic malignancies, discussing the lights and shadows of ICIs, either in under-represented patients with NSCLC in clinical trials, as well as the efficacy of ICIs in thoracic malignancies other than NSCLC.

Lung Cancer and The Immune System

This series of Transl Lung Cancer Res will evaluate current clinical evidence in the still-evolving understanding of the role of ICI in oncogene addicted NSCLC, and the potential pulmonary toxicity associated with ICI.

Lung cancer screening

This special series gives an overview of current evidence and addresses a number of relevant questions related to the implementation of lung cancer screening. We specifically have a close look at the target population, the role of the radiologist in lung cancer screening, diagnosis and management of screen-detected nodules in Asia and Europe, the current role of sublobar resection, implantation of screening programs and finally, the psychological impact of lung cancer screening.

Radiotherapy in thoracic malignancies

In this series of Translational Lung Cancer Research, a group of renowned world experts presents the comprehensive and timely review of state-of-the-art radiation therapy in lung cancer and other thoracic malignancies.

TLCR Annual Report 2021

Welcome to the 2021 annual report for Translational Lung Cancer Research. In 2021, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2021, and we look forward to continuing our work with you in the new year.

‹ ›

Vol 11, No 4 (April, 2022)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Editorial

Will the ultra-low-dose intraoperative X-ray imager change thoracoscopic surgery?

Yoshikane Yamauchi

PDF Pages: 506-508 Full Text COI Form Open Access

Original Article

Identification of heritable rare variants associated with early-stage lung adenocarcinoma risk

Rui Fu, Jia-Tao Zhang, Rong-Rong Chen, Hong Li, Zai-Xian Tai, Hao-Xiang Lin, Jian Su, Xiang-Peng Chu, Chao Zhang, Zhen-Bin Qiu, Zi-Hao Chen, Wen-Fang Tang, Song Dong, Xue-Ning Yang, Guo-Qing Zhang, Guo-Ping Zhao, Yi-Long Wu, Wen-Zhao Zhong

PDF Pages: 509-522 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Macrophages-based immune-related risk score model for relapse prediction in stage I–III non-small cell lung cancer assessed by multiplex immunofluorescence

Xiang-Rong Wu, Hao-Xin Peng, Miao He, Ran Zhong, Jun Liu, Yao-Kai Wen, Cai-Chen Li, Jian-Fu Li, Shan Xiong, Tao Yu, Hong-Bo Zheng, Yan-Hui Chen, Jian-Xing He, Wen-Hua Liang, Xiu-Yu Cai

PDF Pages: 523-542 Full Text Reporting Checklist Peer Review File COI Form Open Access

Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways

Rong Sun, Ryosuke Tanino, Xuexia Tong, Eshat Fahmida Haque, Yoshihiro Amano, Takeshi Isobe, Yukari Tsubata

PDF Pages: 543-559 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Role of radiomics in predicting lung cancer spread through air spaces in a heterogeneous dataset

Massimiliano Bassi, Andrea Russomando, Jacopo Vannucci, Andrea Ciardiello, Miriam Dolciami, Paolo Ricci, Angelina Pernazza, Giulia D’Amati, Carlo Mancini Terracciano, Riccardo Faccini, Sara Mantovani, Federico Venuta, Cecilia Voena, Marco Anile

PDF Pages: 560-571 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma

Wei Guo, Qilin Huai, Tiejun Liu, Guochao Zhang, Naixin Liang, Qianli Ma, Xiang Liu, Fengwei Tan, Qi Xue, Shugeng Gao, Yibo Gao, Jie He

PDF Pages: 572-587 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Ultra-low-dose intraoperative X-ray imager for minimally invasive surgery: a pilot imaging study

Haewook Park, Kook Nam Han, Byeong Hyeon Choi, Hyunsuk Yoon, Hyun Joon An, Jae Sung Lee, Hyun Koo Kim

PDF Pages: 588-599 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Resection and reconstruction via median sternotomy incision for tracheal tumors

Jiaxi He, Chao Yang, Hanyu Yang, Hanzhang Chen, Jianxing He, Shuben Li

PDF Pages: 600-606 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer

Shuhui Cao, Yao Zhang, Yan Zhou, Wenwen Rong, Yue Wang, Xuxinyi Ling, Lincheng Zhang, Jingwen Li, Yusuke Tomita, Satoshi Watanabe, Takeo Nakada, Nobuhiko Seki, Toyoaki Hida, Said Dermime, Runbo Zhong, Hua Zhong

PDF Pages: 607-616 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients

Junnan Feng, Yan Li, Bing Wei, Lei Guo, Weihua Li, Qingxin Xia, Chengzhi Zhao, Jiawen Zheng, Jiuzhou Zhao, Rui Sun, Yongjun Guo, Luka Brcic, Taiki Hakozaki, Jianming Ying, Jie Ma

PDF Pages: 617-631 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Systematic analysis of ferroptosis-related long non-coding RNA predicting prognosis in patients with lung squamous cell carcinoma

Ninghua Yao, Ling Zuo, Xiaodi Yan, Jing Qian, Jie Sun, Huawei Xu, Feifei Zheng, Jimmy T. Efird, Izumi Kawagoe, Yan Wang, Sujie Ni

PDF Pages: 632-646 Full Text Reporting Checklist COI Form Open Access

The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study

Wenjuan Jiang, Yuling Zhou, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Hui Guo, Fabrizio Minervini, Stefano Bongiolatti, Nong Yang, Yongchang Zhang, Min Tao

PDF Pages: 647-655 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases

Juan Zhou, Yinfei Wu, Mengqing Xie, Yujia Fang, Jing Zhao, Sung Yong Lee, Yunjoo Im, Lingyun Ye, Chunxia Su

PDF Pages: 656-669 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk

Bing-Xi He, Yi-Fan Zhong, Yong-Bei Zhu, Jia-Jun Deng, Meng-Jie Fang, Yun-Lang She, Ting-Ting Wang, Yang Yang, Xi-Wen Sun, Lorenzo Belluomini, Satoshi Watanabe, Di Dong, Jie Tian, Dong Xie

PDF Pages: 670-685 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

iMDT Corner

Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report

Han Wu, Junwei Ning, Ziming Li, Duilio Divisi, Antonio Rossi, Alessio Cortellini, Sang-Won Um, Yusuke Okuma, Chiara Lazzari, Qingquan Luo, Tianxiang Chen

PDF Pages: 686-696 Full Text (Video) Reporting Checklist COI Form Open Access

Editorial Commentary

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?

Wolfram C. M. Dempke, Klaus Fenchel, Susanne Reuther, Michael F. Murphy

PDF Pages: 697-701 Full Text Peer Review File COI Form Open Access

Letter to the Editor

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer

Farkhad Manapov, Saskia Kenndoff, Lukas Käsmann

PDF Pages: 702-705 Full Text Peer Review File COI Form Open Access

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Risk factors and outcomes of bronchopleural fistula after bronchoplasty in patients with non-small cell lung cancer: a retrospective multivariate analysis

Zhiyu Peng, Jiandong Mei, Chengwu Liu, Chenglin Guo, Michel Gonzalez, Servet Bölükbas, Luca Voltolini, Qiang Pu, Lunxu Liu

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus^TM integrated sequencer

Siew-Kee Low, Ryo Ariyasu, Ken Uchibori, Rie Hayashi, Hiu Ting Chan, Yoon Ming Chin, Takahiro Akita, Yuhei Harutani, Ayu Kiritani, Ryosuke Tsugitomi, Ryo Manabe, Shinsuke Ogusu, Yoshiaki Amino, Satoru Kitazono, Noriko Yanagitani, Yusuke Nakamura, Makoto Nishio

Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer

Dominika Kaźmierczak, Inger Johanne Zwicky Eide, Radosveta Gencheva, Yi Lai, Rolf Lewensohn, Georgios Tsakonas, Oscar Grundberg, Luigi de Petris, Marc McGowan, Odd Terje Brustugun, Simon Ekman, Per Hydbring

Single nucleotide polymorphisms in FOXP1 and RORA of the lymphocyte activation-related pathway affect survival of lung cancer patients

Hailei Du, Rui Mu, Lihua Liu, Hongliang Liu, Sheng Luo, Edward F. Patz Jr, Carolyn Glass, Li Su, Mulong Du, David C. Christiani, Hecheng Li, Qingyi Wei

Review Article

Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review

Yingbo Huang, Hyeong Joo Cho, Barbara E. Stranger, R. Stephanie Huang

Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review

Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Angela Listì, Edoardo Garbo, Giorgio Vittorio Scagliotti

Are polygenic risk scores ready for the cancer clinic?—a perspective

Robert J. Klein, Zeynep H. Gümüş

Editorial

Liquid biopsies come of age in lung cancer

Petros Christopoulos

Erratum

Erratum to evaluation of PD-L1 expression on circulating tumour cells in small cell lung cancer

Editorial Office

iMDT Corner

Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report

Xiaodong Gu, Wenxian Wang, Wei Wu, Yiping Zhang, Lan Shao, Mariacarmela Santarpia, Petros Christopoulos, Nathaniel J. Myall, Zhiyong Shi, Guangyuan Lou

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.